Argenx Se Stock Price, News & Analysis

On November 7, 2022, argenx (ARGX), a global immunology company, announced its participation in several investor conferences throughout November. Key events include:

• Guggenheim Healthcare Talks: Fireside chat on November 14 at 11:20 a.m. ET, New York.
• Stifel 2022 Healthcare Conference: Fireside chat on November 15 at 4:45 p.m. ET, New York.
• Jefferies London Healthcare Conference: Investor meetings on November 16, London.
• Evercore ISI 5th Annual HealthCONx Conference: Virtual chat on November 29 at 10:55 a.m. ET.
• Piper Sandler 34th Annual Healthcare Conference: Fireside chat on November 30 at 1:00 p.m. ET, New York.

Details on these events can be found on the argenx investor website.

argenx SE reported a strong third quarter 2022, achieving $131 million in global net sales from VYVGART® (efgartigimod alfa-fcab). The company filed a Biologics License Application for a subcutaneous formulation for generalized myasthenia gravis (gMG), with a launch expected in the first half of 2023. Despite high revenue, the company recorded a net loss of $235 million for the quarter. argenx is expanding its pipeline, with multiple ongoing clinical trials targeting severe autoimmune diseases. Management emphasizes growth potential and operational strategies moving forward.

argenx (ARGX) will host a conference call and audio webcast on October 27, 2022, at 2:30 pm CET to discuss its third quarter 2022 financial results and provide a business update. The event can be accessed via the Investors section of the argenx website. The company is known for its commitment to developing novel antibody-based medicines for severe autoimmune diseases, including its first-and-only approved neonatal Fc receptor (FcRn) blocker.

argenx SE (ARGX) announced the submission of a Biologics License Application (BLA) for subcutaneous (SC) efgartigimod to the U.S. FDA for treating generalized myasthenia gravis (gMG) in adults. This follows positive results from the Phase 3 ADAPT-SC trial, where SC efgartigimod demonstrated noninferiority to intravenously administered VYVGART in reducing total immunoglobulin G (IgG) levels after 29 days. Key data included a 66.4% mean reduction in total IgG levels for SC efgartigimod compared to 62.2% for VYVGART. The safety profile was consistent with prior studies, with injection site reactions being the most common side effects.

argenx SE (NASDAQ: ARGX) presented new data at the AANEM Annual Meeting, highlighting the effectiveness and safety of VYVGART (efgartigimod alfa-fcab) for treating generalized myasthenia gravis (gMG). Findings from the ADAPT+ study indicate consistent improvements in patient function and strength over multiple years. New pooled data reveal significant disease score improvements in seronegative gMG patients. The presentations emphasize argenx's commitment to innovation in treating autoimmune diseases, supported by 17 scientific abstracts accepted at the meetings.

argenx announces the appointment of Mrs. Camilla Sylvest as a non-executive director to its Board during an extraordinary general meeting held on September 8, 2022. With extensive experience in scaling global pharmaceutical organizations, Mrs. Sylvest's leadership is expected to enhance company culture and sustainability initiatives. This strategic move aims to strengthen the company's position in the field of immunology and support its mission to advance treatments for severe autoimmune diseases. Further details from the meeting can be found on the company's website.

argenx (Euronext & Nasdaq: ARGX) will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 7, 2022, at 8:00 a.m. E.T. in Boston, MA. The presentation will be accessible via live webcast on the Investors section of the argenx website, with a replay available for 90 days. argenx focuses on treating severe autoimmune diseases and is known for developing the first approved neonatal Fc receptor blocker in the U.S., EU, and Japan, while also advancing multiple experimental medicines.

VYVGART has received approval from the European Commission for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. The approval is based on the Phase 3 ADAPT trial, which showed a 68% response rate on the Myasthenia Gravis Activities of Daily Living scale compared to 30% for placebo (p<0.0001). This therapy is the first neonatal Fc receptor blocker approved in the EU and will provide a targeted treatment option for gMG patients, addressing a significant unmet medical need.

argenx SE, a global immunology company, announced an extraordinary general meeting on September 8, 2022, at 18:30 PM CEST in Amsterdam. The meeting's agenda focuses on the proposed appointment of Mrs. Camilla Sylvest as a non-executive director. Shareholders can attend in person or via proxy voting, with arrangements detailed on the argenx website. The company is recognized for its innovative approach to serious autoimmune diseases, including developing the first approved FcRn blocker in the U.S. and Japan.